Over the past year, we have fortified our oncology capabilities through the acquisition of Prologue Research and the oncology operations of OSI Pharma. The result is the formation of a business unit focused on the unique demands of oncology studies. Together, our new oncology business unit offers a full range of clinical research services for Phase I-IV international or US-based clinical trials in oncology and oncology-related studies.
We’re proud to be focused on making a meaningful difference in the lives of people with cancer.